Vaccines in the Digital Age
CDMOs, don’t miss the train
Navigating the 2020 market
Speed, safety and strict regulatory compliance in vaccine production are essential. However, ensuring both data quality and integrity is difficult to achieve using legacy data management strategies.
In 2018, the global biopharmaceutical market was valued at about $237 billion and is expected to be worth $389 billion by 2024. The vaccine and contract development and manufacturing organization (CDMO) markets are growing with it. In fact, with personalized medicines and chronic diseases driving development, companies outsourced 30% of their drug manufacturing in 2018, and experts expect that will increase to 40%. Today, demand for vaccines against COVID-19 is increasing the pressure further in an already complex and competitive market, and both vaccine manufacturers and CDMOs need to increase their capacity to keep up.
In this eBook, we’ll see how digitally enabling your organization can increase capacity and improve vaccine production. Digital transformation affects every part of the business, from workflow efficiency and safety, to regulatory compliance and faster time-to-market, while also supporting CDMOs on their commitments to their clients as a service provider.
To learn more, download your copy below!
- Poor data management is costing companies millions in rework
- The vaccines market can’t afford to make mistakes down the line
- Complex data must be managed appropriately to get the insight required